Bio-Rad has launched four inhibitory antibodies that are specific to pertuzumab (Perjeta). The company claims these ready-made antibodies inhibit the binding of the drug to its target, human epidermal growth factor 2 (HER2), enabling researchers to develop highly selective and sensitive assays for bioanalysis and drug monitoring of pertuzumab and its biosimilars. The new range of anti-pertuzumab antibodies includes monovalent Fab format antibodies for the development of a pharmacokinetic bridging ELISA to measure free drug, as well as fully human IgG1 antibodies with varying levels of affinity which can be used as a surrogate positive control or reference standard in an anti-drug antibody assay.